About Cytiva
CEVEC's business areas are the development of a platform technology for the production of biopharmaceuticals based on certain human cell lines (CAP cell lines) and the development of selected biopharmaceutical products.
CEVEC was founded in 2001 by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their long experience and collaboration, they recognized the need to develop innovative expression systems for the efficient production of biopharmaceuticals such as recombinant proteins or gene therapy vectors.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Pharma